D. Fowler

发表

Guidelines for the use and interpretation of assays for monitoring autophagy

Robert Clarke, Hong Jiang, Hiroyuki Ishida, 2012 .

Post‐transduction events in retrovirus‐mediated gene therapy involving hematopoietic stem cells: Beyond efficiency issues

J. Medin, D. Fowler, 2002, Journal of cellular biochemistry. Supplement.

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

James Ferrara, Peter A Lachenbruch, Daniel Couriel, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.

A. Barrett, G. Hoehn, M. Bishop, 2007, Experimental hematology.

Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma

R. Gress, D. Fowler, 2000, Leukemia & lymphoma.

NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD

S. Steinberg, A. Berger, S. Mitchell, 2014, Bone Marrow Transplantation.

Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures

S. Steinberg, K. Baird, S. Mitchell, 2014, Bone Marrow Transplantation.

disease: a 28-year experience in the United States Characterization and treatment of chronic active Epstein-Barr virus

W. Wilson, E. Jaffe, S. Pittaluga, 2011 .

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

W. Wilson, E. Jaffe, S. Pittaluga, 2011, Blood.

Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice.

M. Eckhaus, R. Gress, D. Fowler, 1994, Blood.

Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism1

B. Bierer, M. Eckhaus, D. Fowler, 2005, The Journal of Immunology.

Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.

Y. Toda, D. Fowler, J. Mariotti, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rapamycin‐resistant effector T‐cell therapy

D. Fowler, 2014, Immunological reviews.

Th1/Th2 and Tc1/Tc2 Cells

D. Fowler, 2019, Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation.

Tbet is a critical modulator of FoxP3 expression in autoimmune graft-versus-host disease

Samuel J. Taylor, A. Laurence, M. Eckhaus, 2017, Haematologica.

Th1/Th2 and Tc1/Tc2 cells: biology, experimental models and clinical translation

D. Fowler, 2013 .

PD‐1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells

M. Bogyo, R. Berlinguer-Palmini, E. Shevach, 2018, Immunity.

PD-1 Inhibitory Receptor D ownregulates Asparaginyl Endopeptidase and Maintains Foxp 3 Transcription Factor Stability in Induced Regulatory T Cells Graphical

M. Bogyo, R. Berlinguer-Palmini, E. Shevach, 2018 .

Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Thomas E. Hughes, W. Wilson, S. Steinberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted pretransplant host lymphocyte depletion prior to T‐cell depleted reduced‐intensity allogeneic stem cell transplantation

S. Steinberg, M. Bishop, J. Gea-Banacloche, 2004, British journal of haematology.

Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells

J. Medin, D. Fowler, C. Siatskas, 2009, Cancer Gene Therapy.

Are we making progress in GVHD prophylaxis and treatment?

S. Pavletic, D. Fowler, 2012, Hematology. American Society of Hematology. Education Program.

Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.

W. Wilson, S. Steinberg, J. Hou, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Experimental and applied immunotherapy

J. Medin, D. Fowler, 2011 .

National Institutes of Health (NIH) Chronic GVHD Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis

J. Shelhamer, J. Gea-Banacloche, K. Baird, 2013 .

Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation

Sadik H. Kassim, W. Telford, S. Rosenberg, 2013 .

Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer

S. Steinberg, B. Levine, C. June, 2011, Clinical Cancer Research.

IL-2 secretion in vitro and IL-2-driven expansion in vivo receptors directly inhibits 2A Activation of Th1 and Tc1 cell adenosine A

Zhang-Guo Gao, D. Fowler, J. Foley, 2013 .

Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.

S. Steinberg, B. Levine, C. June, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.

M. Bishop, R. Gress, D. Fowler, 2004, Seminars in oncology.

Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant.

W. Wilson, B. Levine, C. June, 2002, Cytotherapy.

Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes

J. Medin, R. Foley, O. Lopez-Perez, 2012, Gene Therapy.

Shared biology of GVHD and GVT effects: potential methods of separation.

D. Fowler, 2006, Critical reviews in oncology/hematology.

T memory stem cell formation: Caveat mTOR

L. Gattinoni, D. Fowler, 2016, EBioMedicine.

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

S. Steinberg, M. Bishop, L. Kwak, 2012, Bone Marrow Transplantation.

Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

V. Kapoor, Kaitlyn E. Ryan, S. Amarnath, 2008, Blood.

Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

I. Pastan, M. Onda, Justin Taylor, 2011, Clinical Cancer Research.

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.

A. Barrett, M. Bishop, J. Tisdale, 2008, Blood.

Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.

J. Medin, J. Bramson, R. Head, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection.

P. Chrobak, M. Livingston, R. Gress, 1998, Blood.

Editorial: Protean effects of IL‐10 include skin self‐defense

D. Fowler, 2012, Journal of leukocyte biology.

Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.

A. Barrett, M. Bishop, R. Childs, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cells Preponderance of CD4+ Effector Memory Cells Relative to Central Memory Severe Chronic Graft-Versus-Host Disease is Characterized by a

A. Barrett, M. Bishop, R. Childs, 2013 .

Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.

G. Illei, A. Barrett, M. Bishop, 2004, Blood.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients

S. Steinberg, J. Zolton, K. Baird, 2018, Bone Marrow Transplantation.

Graft-vs.-Host Disease as a Th1-Type Process: Regulation by Th2-Type Cells

R. Gress, D. Fowler, 2004 .

Rapamycin-Resistant T Cells and Pentostatin-Based Immuno-Selective Conditioning for the Allogeneic T Cell Therapy of Cancer

D. Fowler, D. Halverson, David C. Halverson, 2015 .

Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.

S. Steinberg, M. Bishop, R. Gress, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.

Justin Taylor, Kaitlyn E. Ryan, S. Amarnath, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone Marrow‐Derived Mesenchymal Stromal Cells Harness Purinergenic Signaling to Tolerize Human Th1 Cells In Vivo

M. Sabatino, A. Barrett, A. Laurence, 2015, Stem cells.

EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT

S. Steinberg, M. Bishop, S. Neelapu, 2011, Bone Marrow Transplantation.

Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells.

M. Sabatino, D. Stroncek, P. Jin, 2013, Cytotherapy.

Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model

J. Medin, D. Spaner, J. Bramson, 2011, Gene Therapy.

Propagation of mouse and human T cells with defined antigen specificity and function.

B. Czerniecki, S. Rosenberg, R. Gress, 1994, Ciba Foundation symposium.

90 Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin’s Lymphoma

T. Waldmann, S. Pittaluga, M. Brechbiel, 2020 .

Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.

S. Steinberg, M. Bishop, D. Danforth, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma.

E. Jaffe, D. Fowler, M. Ozdemirli, 2007, The American journal of surgical pathology.

Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD

Daniel M. Konecki, B. Levine, C. June, 2010, Autophagy.

Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1

W. Telford, B. Levine, C. June, 2010, PLoS biology.

Rapamycin Resistant Murine Th9 Cells Have a Stable In Vivo Phenotype and Inhibit Graft-Versus-Host Reactivity

D. Fowler, P. Massey, Shoba Amarnath, 2013, PloS one.

Disease and Graft-versus-Tumor Effects via Graft-versus-Host Cells That Potently Inhibit Ex Vivo Rapamycin Generates Donor Th2

B. Bierer, M. Eckhaus, D. Fowler, 2013 .

IL-4-Dependent Mechanism Disease and Graft-versus-Tumor Effects via Graft-versus-HostCells That Potently Inhibit Ex Vivo Rapamycin Generates Donor Th 2

B. Bierer, M. Eckhaus, D. Fowler, 2005 .

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Biomarkers for Chronic Graft-versus-Host isease : National Institutes of Health Consensus evelopment Project on Criteria for Clinical Trials n Chronic Graft-versus-Host Disease : III . Biomarker orking Group Report

P. Lachenbruch, D. Miklos, E. Holler, 2006 .

Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence

A. Barrett, D. Stroncek, J. Tisdale, 2018, Transfusion.

Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells.

A. Poeppl, J. Medin, S. Liang, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

S. Steinberg, S. Pittaluga, B. Levine, 2012, Blood.

Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced intensity allogeneic hematopoietic cell transplantation

S. Steinberg, M. Bishop, S. Pollack, 2007 .

Th1/Th2 cytokine production efficacy of daclizumab independently of its effects on cell division and Direct inhibition of CD40L expression can contribute to the clinical

H. Azmi, J. Hou, J. T. Snyder, 2013 .

Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production.

H. Azmi, J. Hou, J. T. Snyder, 2007, Blood.

Direct inhibition of CD 40 L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th 1 / Th 2 cytokine production

H. Azmi, J. Hou, J. T. Snyder, 2007 .

Interleukin 7 worsens graft-versus-host disease.

T. Fry, C. Mackall, G. Miller, 2002, Blood.

Lentivirus-mediated gene therapy for Fabry disease

J. Medin, C. Morel, Aneal Khan, 2021, Nature Communications.

Selection and expansion of T cell from untreated patients with CLL: source of cells for immune reconstitution?

J. Williams, E. Read, R. Gress, 2000, Cytotherapy.

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

W. Wilson, S. Steinberg, M. Bishop, 2006 .

blood stem cell mobilization in an ethnically diverse population Donor demographic and laboratory predictors of allogeneic peripheral

M. Bishop, J. Tisdale, R. Childs, 2013 .

Host-Based Th2 Cell Therapy for Prolongation of Cardiac Allograft Viability

M. A. Solomon, D. Fowler, Hao Chen, 2011, PloS one.

Programmed death-1 receptor signaling downregulates asparaginyl endopeptidase to maintain Foxp3 stability in induced Regulatory T cells

M. Bogyo, E. Shevach, A. Laurence, 2018 .

Fas‐mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL‐expressing T cells

E. Read, R. Gress, V. Fellowes, 1999, British journal of haematology.

Hydrogen Sulfide Is an Endogenous Potentiator of T Cell Activation*

D. Roberts, S. Kaur, D. Fowler, 2011, The Journal of Biological Chemistry.

Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.

M. Eckhaus, R. Gress, D. Fowler, 1996, Journal of immunology.

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

J. Hou, J. Medin, D. Peace, 2005, Cancer Gene Therapy.

Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment.

R. Gress, P. Cohen, D. Fowler, 1994, Journal of immunology.

Interleukin-7 Worsens Graft-vs-Host Disease

T. Fry, C. Mackall, G. Miller, 2002 .

Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

S. Steinberg, R. Gale, M. Bishop, 2013, Experimental hematology.

Non-myeloablative allogeneic hematopoietic stem cell transplantation with pre-transplant immune depletion results in rapid full donor engraftment in pediatric patients with malignancy

M. Bishop, T. Fry, C. Mackall, 2004 .

An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.

M. Eckhaus, J. Williams, R. Gress, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.

M. Eckhaus, D. Fowler, J. Foley, 2003, Blood.

CD8+ T Cells of Tc2 Phenotype Mediate a GVL Effect and Prevent Marrow Rejection

R. Gress, D. Fowler, 1998, Vox sanguinis.

Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

A. Lavie, J. Medin, Takeya Sato, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies

M. Sabatino, D. Stroncek, V. Fellowes, 2014, Journal of Translational Medicine.

Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.

S. Steinberg, M. Bishop, T. Fry, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of Hepatic Dysfunction in subjects diagnosed with Chronic GVHD by NIH Consensus Criteria.

D. Kleiner, C. Koh, S. Pavletic, 2022, Transplantation and cellular therapy.

Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases.

Stephanie N. Hicks, Thomas E. Hughes, S. Steinberg, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders

J. Medin, C. A. Rupar, S. R. Foley, 2022, EMBO molecular medicine.

Functionally defined T cell subsets in transplantation biology and therapy: regulatory T cells and Th2 cells.

M. Edinger, P. Hoffmann, D. Fowler, 2009, Cancer treatment and research.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Vincristine therapy for mast cell tumors in dogs.

M. Miller, D. Knapp, S. Withrow, 1997, Journal of veterinary internal medicine.

Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice

S. Steinberg, S. Mitchell, M. Datiles, 2015, Haematologica.

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.

S. Steinberg, M. Bishop, J. Gea-Banacloche, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

S. Steinberg, I. Pastan, M. Miettinen, 2013, Science Translational Medicine.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

S. Rosenberg, J. Gea-Banacloche, S. Feldman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.

M. Eckhaus, Kaitlyn E. Ryan, Michael Eckhaus, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Sadik H. Kassim, W. Telford, S. Rosenberg, 2013, Blood.

Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.

M. Konrad, A. Lavie, J. Medin, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease

A. Schambach, J. Medin, C. Morel, 2023, Molecular therapy. Methods & clinical development.

FACTs Fabry gene therapy clinical trial: Two-year data

J. Medin, Aneal Khan, D. Barber, 2019, Molecular Genetics and Metabolism.

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

Ash A. Alizadeh, James B. Mitchell, L. Staudt, 2004, Blood.

Harnessing autophagy for adoptive T-cell therapy.

D. Fowler, Shoba Amarnath, 2012, Immunotherapy.

Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity

Takeshi Mizutani, Jayakrishna Ambati, Paul Kubes, 2014, Science.

Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways

J. Medin, G. Dekaban, D. Fowler, 2013, Virology Journal.

In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype.

R. Gress, D. Fowler, G. Schwartz, 1997, Blood.

Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection1

W. Telford, A. Fojo, J. Trepel, 2008, The Journal of Immunology.

Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis.

E. Jaffe, L. Medeiros, M. Stetler-Stevenson, 1993, Archives of pathology & laboratory medicine.

Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument

Opal L. Reddy, D. Stroncek, C. Mackall, 2019, Clinical hematology international.

The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells

B. Levine, C. June, J. Medin, 2011, Science Translational Medicine.

Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity

W. Telford, Mollie H. Wright, L. Varticovski, 2008, BMC Cancer.

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

J. Ritz, D. Miklos, M. V. D. van den Brink, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T cells helping GVHD: take-away lessons.

D. Fowler, 2009, Blood.

Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.

Y. Toda, D. Fowler, J. Foley, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma.

T. Waldmann, S. Pittaluga, M. Brechbiel, 2020, Cancer biotherapy & radiopharmaceuticals.

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Jamie B. Spangler, Eric O Long, T. Waldmann, 2015, Immunity.

National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

J. Shelhamer, S. Steinberg, J. Gea-Banacloche, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis.

M. Haley, D. Fowler, A. Retter, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Allogeneic and Autologous Transplantation Therapy of Cancer: Converging Themes

D. Fowler, 2011 .

Animal Models of Acute and Chronic Graft‐Versus‐Host Disease

G. Shearer, R. Gress, F. Hakim, 1998, Current protocols in immunology.

Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma

S. Steinberg, M. Bishop, S. Pollack, 2010, Cancer.

Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

S. Steinberg, M. Bishop, T. Fry, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.

W. Wilson, S. Steinberg, M. Bishop, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.

S. Steinberg, M. Bishop, S. Kummar, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity

S. Steinberg, M. Bishop, K. Baird, 2011, Leukemia.

Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation

M. Bishop, D. Stroncek, S. Pavletic, 2014, Transfusion.

Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

S. Steinberg, M. Bishop, S. Pavletic, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.

S. Steinberg, M. Bishop, J. Gea-Banacloche, 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Chronic graft-versus-host disease in the era of reduced-intensity conditioning

S. Pavletic, D. Fowler, Deepa S. Subramaniam, 2007, Leukemia.

Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

K. Jacobson, Zhang-Guo Gao, D. Fowler, 2005, Blood.

Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise

R. Gress, D. Fowler, 2005 .

Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.

W. Quint, Sarah Wagner, M. Schiffman, 2020, JAMA oncology.

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

S. Steinberg, M. Sabatino, B. Levine, 2013, Blood.

Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.

S. Steinberg, S. Pittaluga, M. Bishop, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

S. Steinberg, A. Fojo, B. Levine, 2015, Clinical Cancer Research.

Stem Cell Graft Rejection Persist In Vivo and Prevent Hemopoietic Apoptosis-Resistant Donor Th 2 Cells That Ex Vivo Rapamycin Generates

W. Telford, A. Fojo, J. Trepel, 2007 .

STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease.

J. O’Shea, A. Laurence, M. Eckhaus, 2012, Immunity.

IL-27: a new target for GVHD prevention.

D. Fowler, Shoba Amarnath, 2016, Blood.

A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis

S. Steinberg, J. LoPiccolo, R. Memmott, 2009, PloS one.

induces a p 53-dependent gene expression response Fludarabine treatment of patients with chronic lymphocytic leukemia

Ash A. Alizadeh, James B. Mitchell, Arthur, 2004 .

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease

S. Davis, W. Telford, D. Stroncek, 2016, The Journal of Immunology.

Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.

R. Gress, D. Fowler, G. Nagel, 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PD-1 regulates KLRG1+ group 2 innate lymphoid cells

Samuel J. Taylor, W. Paul, N. Reynolds, 2017, The Journal of experimental medicine.

Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Survivors: A Study Protocol

A. Barrett, M. Bishop, L. Wehrlen, 2011, Health and quality of life outcomes.

Syk and tired of current chronic GVHD therapies.

S. Pavletic, D. Fowler, 2015, Blood.

Harnessing autophagy for cell fate control gene therapy

J. Medin, B. Dropulić, D. Fowler, 2013, Autophagy.

Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.

S. Steinberg, A. Im, K. Baird, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

A. Barrett, T. Fry, J. Tisdale, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease

J. Shelhamer, Stephanie J. Lee, J. Gea-Banacloche, 2013 .

Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation

H. Holte, T. Egeland, I. Dybedal, 2012, Bone Marrow Transplantation.

Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity.

S. Rosenberg, J. Mulé, R. Alexander, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.

S. Steinberg, M. Bishop, S. Pollack, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.

M. Bishop, Li Yang, L. Wehrlen, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor Lymphocyte Infusion

D. Fowler, D. Halverson, 2020, Definitions.

Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.

D. Mollura, U. Bagci, Brent Foster, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

allosensitization generates distinct GVT and GVHD effects CD3/CD28-costimulated T1 and T2 subsets: differential in vivo

M. Eckhaus, D. Fowler, J. Foley, 2013 .

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)

N. Leidy, K. Mooney, P. Palit, 2010, Bone Marrow Transplantation.

B-ware of allosensitized graft rejection

D. Fowler, 2007 .

Anti-Mesothelin Immunotoxin and Immune Suppression Major Cancer Regressions in Mesothelioma After Treatment with an

S. Steinberg, I. Pastan, M. Miettinen, 2013 .

Doubling down on PKC benefits allogeneic BMT.

D. Fowler, 2013, Blood.

Squamous cell carcinoma of the pancreas with cystic degeneration.

D. Fowler, J. Schor, J. Colarian, 2000, Southern medical journal.